A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.

被引：1
|
作者：
Hellmann, Matthew David
Shimizu, Toshio
Doi, Toshihiko
Hodi, F. Stephen
Rottey, Sylvie
Aftimos, Philippe Georges
Liu, Zhuqing Tina
de Mendizabal, Nieves Velez
Szpurka, Anna M.
Piao, Yongzhe
Vangerow, Burkhard
Gandhi, Leena
Leow, Ching Ching
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] NCCH, Tokyo, Japan
[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Ghent Univ Hosp, Heymans Inst Pharmacol, Ghent, Belgium
[7] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Eli Lilly Japan KK, Kobe, Hyogo, Japan
[10] Eli Lilly & Co, Bad Homburg, Germany
[11] NYU Perlmutter Canc Ctr, New York, NY USA
[12] Eli Lilly & Co, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS2654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2654
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors
    Bhumsuk Keam
    Chan-Young Ock
    Tae Min Kim
    Do-Youn Oh
    Won Ki Kang
    Yeon Hee Park
    Jeeyun Lee
    Ji Hye Lee
    Yoen Hee Ahn
    Hyeon Ju Kim
    Sook Kyung Chang
    Jihyun Park
    Ji Yea Choi
    Yun Jeong Song
    Young Suk Park
    Investigational New Drugs, 2021, 39 : 1624 - 1632
  • [42] A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors
    Keam, Bhumsuk
    Ock, Chan-Young
    Kim, Tae Min
    Oh, Do-Youn
    Kang, Won Ki
    Park, Yeon Hee
    Lee, Jeeyun
    Lee, Ji Hye
    Ahn, Yoen Hee
    Kim, Hyeon Ju
    Chang, Sook Kyung
    Park, Jihyun
    Choi, Ji Yea
    Song, Yun Jeong
    Park, Young Suk
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1624 - 1632
  • [43] Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab
    Kyi, Chrisann
    Van Dongen, Marloes
    Rottey, Sylvie
    Bermejo, Ignacio Melero
    Mittag, Diana
    Gouveia, Dane
    Bol, Kees
    Yan, Chris
    Joe, Andrew K.
    Laus, Gianluca
    Moreno, Victor
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
    Deva, S.
    Lee, J-S.
    Lin, C-C.
    Yen, C-J.
    Millward, M.
    Chao, Y.
    Keam, B.
    Jameson, M.
    Hou, M-M.
    Kang, Y-K.
    Markman, B.
    Lu, C-H.
    Rau, K-M.
    Lee, K-H.
    Horvath, L.
    Friedlander, M.
    Hill, A.
    Wu, J.
    Hou, J.
    Desai, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors
    Zielinski, Christoph C.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 406 - 407
  • [46] A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors
    Weiss, Glen J.
    Luke, Jason J.
    Falchook, Gerald
    Eroglu, Zeynep
    Wang, Judy
    Hamilton, Erika
    Hecht, J. Randolph
    LoRusso, Patricia
    Eder, Joseph Paul
    Hughes, Lorraine
    Wang, Jing
    Running, Kelli
    McEachern, Kristen
    Bobilev, Dmitri
    Ribas, Antoni
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [47] A phase 1 study of IMC-001, novel anti-PD-L1 antibody, in patients with advanced solid tumors
    Keam, Bhumsuk
    Kim, Tae Min
    Oh, Do-Youn
    Ock, Chan-Young
    Kang, Won Ki
    Park, Yeon Hee
    Lee, Jeeyun
    Lee, Ji Hye
    Song, Yun Jeong
    Park, Young Suk
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [48] Phase I study of anti-PD-L1 antibody MPDL3280A in patients with advanced solid tumors
    Murakami, Haruyasu
    Yamamoto, Noboru
    Kenmotsu, Hirotsugu
    Takahashi, Toshiaki
    Fujiwara, Yutaka
    Mizugaki, Hidenori
    Ishida, Yoshimasa
    Kawakami, Tomohisa
    ANNALS OF ONCOLOGY, 2015, 26 : 98 - 98
  • [49] A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors
    Markman, Ben
    Tran, Ben
    Gan, Hui
    Prawira, Amy
    Coward, Jermaine
    Jin, Xiaoping
    Li, Baiyong
    Wang, Max
    Xia, Yu
    Desai, Jayesh
    Millward, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [50] GEN1046 (Bispecific Antibody Targeting PD-L1 and 4-1BB): Preclinical Characteristics and Phase 1 Results in Solid Tumors
    Kunkel, Maria
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Schodel, Kristina
    Diken, Mustafa
    Sette, Angelica
    Stanganello, Eliana
    Vascotto, Fulvia
    Breij, Esther
    Sasser, Kate
    Tureci, Ozlem
    Forssmann, Ulf
    Ahmadi, Tahamtan
    Sahin, Ugur
    CANCER SCIENCE, 2023, 114 : 1566 - 1566
12345